This trial is to find out the best dose of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS) lymphoma. Lenalidomide may stop or slow primary CNS lymphoma by blocking the growth of new blood vessels necessary for tumor growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread.
- Central Nervous System Lymphoma
- Non-Hodgkin's Lymphoma
2 Primary · 4 Secondary · Reporting Duration: Up to 5 years
Side Effects for
Awards & Highlights
1 Treatment Group
Treatment (rituximab, methotrexate, lenalidomide, nivolumab)
1 of 1
32 Total Participants · 1 Treatment Group
Primary Treatment: Lenalidomide · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the current regulatory status of Lenalidomide?
"Lenalidomide scores 1 out of 3 on our safety scale as it is a Phase 1 trial, meaning there are few studies to support efficacy and limited evidence related to safety." - Anonymous Online Contributor
Are there currently opportunities to participate in this trial?
"Affirmative. According to information on clinicaltrials.gov, this trial is still admitting individuals for participation and was initially posted in January 2021 with the most recent update occurring in November 2022. A total of 32 patients are required from a pool of 32 medical centres involved in the study." - Anonymous Online Contributor
Has lenalidomide been subject to previous research studies?
"In 1993, lenalidomide's clinical trials first began at the National Institutes of Health Clinical Center located in Rockville Pike. Since then, a total of 1908 different studies have been completed with 1487 still running today; many are hosted by Weston, Wisconsin." - Anonymous Online Contributor
In what circumstance is Lenalidomide most commonly prescribed?
"Primarily, lenalidomide is administered to those with metastatic urothelial carcinoma of the ureter. Yet this therapeutic agent may also aid individuals suffering from malignant melanoma of skin, chronic lymphocytic leukemia, and metastatic hepatocellular carcinoma." - Anonymous Online Contributor
How widely distributed is this clinical test being performed?
"This experiment is being conducted at Marshfield Medical Center - Weston in Weston, Wisconsin, Huntsman Cancer Institute/University of Utah in Salt Lake City, Utah and at Marshfield Medical Center-Rice Lake in Rice Lake, Texas. Moreover, 32 additional sites are involved as well." - Anonymous Online Contributor
To what extent are participants enrolled in this clinical experiment?
"To fulfill the requirements of this trial, 32 eligible patients need to be enrolled. Those seeking participation can visit Marshfield Medical Center - Weston in Weston, Wisconsin and Huntsman Cancer Institute/University of Utah in Salt Lake City, Utah for further details." - Anonymous Online Contributor
What is the intent of this medical experiment?
"The primary purpose of this 6 month clinical trial is to determine the Maximum Tolerated Dose (MTD). Secondary objectives include estimating Overall Response Rate, Incidence of Adverse Events and Progression-Free Survival. For each outcome, descriptive statistics will be employed such as exact binomial 95% confidence intervals for response rate and Kaplan-Meier estimates for PFS." - Anonymous Online Contributor